BlackRock, Inc. 13D and 13G filings for Iovance Biotherapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-07-17 8:12 pm Purchase | 2025-06-30 | 13G | Iovance Biotherapeutics, Inc. IOVA | BlackRock Inc. BLK | 21,305,651 6.400% | 2,233,895 (+11.71%) | Filing |
| 2024-01-26 11:49 am Purchase | 2023-12-31 | 13G | Iovance Biotherapeutics, Inc. IOVA | BlackRock Inc. BLK | 19,071,756 7.500% | 6,995,480 (+57.93%) | Filing |
| 2023-02-03 12:10 pm Purchase | 2022-12-31 | 13G | Iovance Biotherapeutics, Inc. IOVA | BlackRock Inc. BLK | 12,076,276 7.700% | 4,667,771 (+63.01%) | Filing |
| 2022-02-24 5:23 pm Sale | 2021-12-31 | 13G | Iovance Biotherapeutics, Inc. IOVA | BlackRock Inc. BLK | 7,408,505 4.700% | -1,594,083 (-17.71%) | Filing |
| 2021-01-29 09:57 am Sale | 2020-12-31 | 13G | Iovance Biotherapeutics, Inc. IOVA | BlackRock Inc. BLK | 9,002,588 6.100% | -592,072 (-6.17%) | Filing |